EGF-receptor targeting with monoclonal antibodies in colorectal carcinomas: rationale for a pharmacogenomic approach

Author： Loupakis Fotios   Vasile Enrico   Santini Daniele   Masi Gianluca   Falcone Alfredo   Graziano Francesco  

Publisher： Future Medicine

ISSN： 1462-2416

Source： Pharmacogenomics, Vol.9, Iss.1, 2008-01, pp. : 55-69

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Monoclonal Antibodies Targeting the Epidermal Growth Factor Receptor

By  

Current Drug Targets, Vol. 6, Iss. 3, 2005-05 ,pp. : 275-287

Bentham Science Publishers

Access to resources Recommend Favorite

The History and Rationale for Monoclonal Antibodies in the Treatment of Hematologic Malignancy

By  

Current Pharmaceutical Biotechnology, Vol. 2, Iss. 4, 2001-12 ,pp. : 293-300

Bentham Science Publishers

Access to resources Recommend Favorite

Targeting Receptor Tyrosine Kinases Using Monoclonal Antibodies: The Most Specific Tools for Targeted-Based Cancer Therapy

By  

Current Drug Targets, Vol. 17, Iss. 14, 2016-11 ,pp. : 1687-1703

Bentham Science Publishers

Access to resources Recommend Favorite

The Synergistic Effect of Humanized Monoclonal Antibodies Targeting Insulin-Like Growth Factor 1 Receptor (IGF-1R) and Chemotherapy

By  

Current Drug Targets, Vol. 15, Iss. 7, 2014-06 ,pp. : 674-680

Bentham Science Publishers

Access to resources Recommend Favorite

Targeting Epidermal Growth Factor Receptor in Solid Tumors: Critical Evaluation of the Biological Importance of Therapeutic Monoclonal Antibodies

By  

Current Medicinal Chemistry, Vol. 16, Iss. 29, 2009-01 ,pp. : 3797-3804

Bentham Science Publishers

Access to resources Recommend Favorite